Cardioprotective Effect of Quercetin and Sitagliptin in Doxorubicin-Induced Cardiac Toxicity in Rats

References

• Shaito A, Thuan DTB, Phu HT, et al. Herbal medicine for cardiovascular diseases: efficacy, mechanisms, and safety. Front Pharmacol. 2020;11(April):1–32. doi:10.3389/fphar.2020.0042232116689
   PubMed Web of Science ®Google Scholar
• Ferdinandy P, Baczkó I, Bencsik P, et al. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J. 2019;40(22):1771–1777C. doi:10.1093/eurheartj/ehy36529982507
   PubMed Web of Science ®Google Scholar
• McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75. doi:10.1007/s10557-016-6711-028185035
   PubMed Web of Science ®Google Scholar
• Nayebi M. Ultrastructural and echocardiographic assessment of chronic doxorubicin-induced cardiotoxicity in rats. Arch Razi Inst. 2020;75(1):56. doi:10.22092/ARI.2019.116862.1177
   Google Scholar
• Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways. Pharmacogenet Genomics. 2011;21(7):440–446. doi:10.1097/fpc.0b013e32833ffb5621048526
   PubMed Web of Science ®Google Scholar
• Reiner Ž, Laufs U, Cosentino F, Landmesser U. The year in cardiology 2018: prevention. Eur Heart J. 2019;40(4):336–344. doi:10.1093/eurheartj/ehy89430601998
   PubMed Web of Science ®Google Scholar
• Singh S, Sedha S. Medicinal plants and their pharmacological aspects. FPI. 2018;1(4):156–170.
   Google Scholar
• Varga E, Bodi A, Ferdinandy P, Droy-Lefaix MT, Blasig IE, Tosaki A. The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts: a link between cardiac function and nitric oxide production. J Cardiovasc Pharmacol. 1999;34(5):711–717. doi:10.1097/00005344-199911000-0001310547088
   PubMed Web of Science ®Google Scholar
• Pataki T, Bak I, Kovacs P, Bagchi D, Das DK, Tosaki A. Grape seed proanthocyanidins improved cardiac recovery during reperfusion after ischemia in isolated rat hearts. Am J Clin Nutr. 2002;75(5):894–899. doi:10.1093/ajcn/75.5.89411976164
   PubMed Web of Science ®Google Scholar
• Bak I, Lekli I, Juhasz B, et al. Isolation and analysis of bioactive constituents of sour cherry (Prunus cerasus) seed kernel: an emerging functional food. J Med Food. 2010;13(4):905–910. doi:10.1089/jmf.2009.018820482278
   PubMed Web of Science ®Google Scholar
• Czompa A, Gyongyosi A, Czegledi A, et al. Cardioprotection afforded by sour cherry seed kernel: the role of heme oxygenase-1. J Cardiovasc Pharmacol. 2014;64(5):412–419. doi:10.1097/FJC.000000000000013224949584
   PubMed Web of Science ®Google Scholar
• Csiki Z, Papp-Bata A, Czompa A, et al. Orally delivered sour cherry seed extract (SCSE) affects cardiovascular and hematological parameters in humans. Phytother Res. 2015;29(3):444–449. doi:10.1002/ptr.527325640007
   PubMed Web of Science ®Google Scholar
• Jing Z, Wang Z, Li X, et al. Protective effect of quercetin on posttraumatic cardiac injury. Sci Rep. 2016;6(1):(February):1–10. doi:10.1038/srep30812
   Web of Science ®Google Scholar
• Shah P, Upaganlawar A, Balaraman R. Combined cardioprotective effects of quercetin and curcumin on doxorubicin induced cardiotoxicity in rats. Pharmacogn Mag. 2008;4(16SUPPL):246–250.
   Google Scholar
• Zhou Y, Guo Z, Yan W, Wang W. Cardiovascular effects of sitagliptin – an anti-diabetes medicine. Clin Exp Pharmacol Physiol. 2018;45(7):628–635. doi:10.1111/1440-1681.1295329679391
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary. Endocr Pract. 2019;25(1):69–100. doi:10.4158/CS-2018-053530742570
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi:10.1056/nejmoa150135226052984
   PubMed Web of Science ®Google Scholar
• Rehman MB, Tudrej BV, Soustre J, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017;43(1):48–58. doi:10.1016/j.diabet.2016.09.00527745828
   PubMed Web of Science ®Google Scholar
• Yang TY, Liaw YP, Huang JY, Chang HR, Chang KW, Ueng KC. Association of sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study. Acta Diabetol. 2016;53(3):461–468. doi:10.1007/s00592-015-0817-x26687195
   PubMed Web of Science ®Google Scholar
• Ahmed ZA, Abtar AN, Othman HH, Aziz TA. Effects of quercetin, sitagliptin alone or in combination in testicular toxicity induced by doxorubicin in rats. Drug Des Devel Ther. 2019;13(September):3321–3329. doi:10.2147/DDDT.S222127
   PubMed Web of Science ®Google Scholar
• Bo MS, Cheah WL, Lwin S, Moe Nwe T, Win TT, Aung M. Understanding the relationship between atherogenic index of plasma and cardiovascular disease risk factors among staff of an university in Malaysia. J Nutr Metab. 2018;2018:2015. doi:10.1155/2018/7027624
   Web of Science ®Google Scholar
• Calling S, Johansson SE, Wolff M, Sundquist J, Sundquist K. The ratio of total cholesterol to high density lipoprotein cholesterol and myocardial infarction in women’s health in the Lund area (WHILA): a 17-year follow-up cohort study. BMC Cardiovasc Disord. 2019;19(1):1–9. doi:10.1186/s12872-019-1228-730606129
   PubMed Web of Science ®Google Scholar
• Rochette L, Guenancia C, Gudjoncik A, et al. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci. 2015;36(6):326–348. doi:10.1016/J.TIPS.2015.03.00525895646
   PubMed Web of Science ®Google Scholar
• Kelleni MT, Abdelbasset M. Drug induced cardiotoxicity: mechanism, prevention and management. Cardiotoxicity. 2018. doi:10.5772/intechopen.79611
   Google Scholar
• Viswanatha Swamy AHM, Wangikar U, Koti BC, Thippeswamy AHM, Ronad PM, Manjula DV. Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats. Indian J Pharmacol. 2011;43(5):507–511. doi:10.4103/0253-7613.8495222021990
   PubMed Web of Science ®Google Scholar
• Hasić S, Jadrić R, Kiseljaković E, Mornjaković Z, Winterhalter-Jadrić M. Troponin T and histological characteristics of rat myocardial infarction induced by isoproterenol. Bosn J BASIC Med Sci. 2007;7(3):212–217. doi:10.17305/bjbms.2007.304617848144
   PubMed Web of Science ®Google Scholar
• Kopel E, Kivity S, Morag-Koren N, Segev S, Sidi Y. Relation of serum lactate dehydrogenase to coronary artery disease. Am J Cardiol. 2012;110(12):1717–1722. doi:10.1016/j.amjcard.2012.08.00522981267
   PubMed Web of Science ®Google Scholar
• Jensen DM. Approach to asymptomatic creatine kinase elevation. Physiol Behav. 2018;176(1):1570–1573. doi:10.1038/s41395-018-0061-4
   Web of Science ®Google Scholar
• Zhang M, Swarts SG, Yin L, et al. Antioxidant properties of quercetin. In: Advances in Experimental Medicine and Biology. Vol. 701. 2011: 283–289. doi:10.1007/978-1-4419-7756-4_3821445799
   PubMed Web of Science ®Google Scholar
• Civantos E, Bosch E, Ramirez E, et al. Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway. Diabetes Metab Syndr Obes. 2017;10:207–222. doi:10.2147/DMSO.S13253728652790
   PubMed Web of Science ®Google Scholar
• Hrelia S, Fiorentini D, Maraldi T, et al. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta. 2002;1567(SUPPL):150–156. doi:10.1016/S0005-2736(02)00612-012488048
   PubMed Web of Science ®Google Scholar
• Arunachalam S, Tirupathi Pichiah PB, Achiraman S. Doxorubicin treatment inhibits PPARγ and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models. FEBS Lett. 2013;587(2):105–110. doi:10.1016/j.febslet.2012.11.01923219922
   PubMed Web of Science ®Google Scholar
• Eitah HE, Maklad YA, Abdelkader NF, Gamal El Din AA, Badawi MA, Kenawy SA. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats. Toxicol Appl Pharmacol. 2019;365:30–40. doi:10.1016/J.TAAP.2018.12.01130576699
   PubMed Web of Science ®Google Scholar
• Nuransoy A, Beytur A, Polat A, Samdanci E, Sagir M, Parlakpinar H. Renal failure protective effect of sitagliptin against renal ischemia reperfusion injury in rats protective effect of sitagliptin against renal ischemia reperfusion injury in rats. Ren Fail. 2015;37(4):687–693. doi:10.3109/0886022X.2015.101099125703705
   PubMed Web of Science ®Google Scholar
• D’Andrea G. Quercetin: a flavonol with multifaceted therapeutic applications? Fitoterapia. 2015;106:256–271. doi:10.1016/j.fitote.2015.09.01826393898
   PubMed Web of Science ®Google Scholar
• Chen S, Jiang H, Wu X, Fang J. Therapeutic effects of quercetin on inflammation, obesity, and type 2 diabetes. Mediators Inflamm. 2016;2016(Article ID 9340637):5. doi:10.1155/2016/9340637
   Web of Science ®Google Scholar
• Majeed SA, Hadi NR, Al Mudhafar AM, Al-Janabi HA. Sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways. SAGE Open Med. 2013;1:205031211349991. doi:10.1177/2050312113499912
   Google Scholar
• Nayagam AAJ, Gunasekaran S, Rangarajan S, Muthaiah S. Myocardial potency of Caesalpinia bonducella Linn. on doxorubicin induced myocardial infarction in albino rats. Clin Phytoscience. 2019;5(1). doi:10.1186/s40816-019-0146-7
   Google Scholar
• Chennuru A, Saleem MTS. Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. Biomed Res Int. 2013;2013:934239. doi:10.1155/2013/93423924228260
   PubMed Web of Science ®Google Scholar
• Derakhshanian H, Djalali M, Djazayery A, et al. Quercetin ameliorates lipid and apolipoprotein profile in high-dose glucocorticoid treated rats. Arq Bras Cardiol. 2020;115(1):102–108. doi:10.36660/abc.2018039732813833
   PubMed Web of Science ®Google Scholar
• Huang H, Liao D, Dong Y, Pu R. Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: a systematic review and meta-analysis. Nutr Rev. 2020;78(8):615–626. doi:10.1093/nutrit/nuz07131940027
   PubMed Web of Science ®Google Scholar
• Patel RV, Mistry BM, Shinde SK, Syed R, Singh V, Shin HS. Therapeutic potential of quercetin as a cardiovascular agent. Eur J Med Chem. 2018;155:889–904. doi:10.1016/j.ejmech.2018.06.05329966915
   PubMed Web of Science ®Google Scholar
• Jia Q, Cao H, Shen D, et al. Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1. Int J Mol Med. 2019;44(3):893–902. doi:10.3892/ijmm.2019.426331524223
   PubMed Web of Science ®Google Scholar